Sales continue to significantly increase

MKTUPDTE

Thu, Dec 12 2024 03:36 pm

As we approach the half-year mark, we can report strong momentum in our sales performance across our key markets. Our revenue is forecast to exceed $600,000 (unaudited) for the six-month period, and we expect to have unaudited sales of approximately $400,000 for the October to December quarter. This will be approximately 80% growth quarter-on-quarter.

This significant growth reflects our increased presence in both domestic and international markets.

[SEE GRAPH IN ATTACHMENT]

Germany

We continue to expand our product portfolio in this market, with the launch of a new product in December. This reinforces our position in Europe’s largest medicinal cannabis market, with increased sales expected over the coming months..

Australia

Our sales in this large but competitive market are steadily growing, with our distribution channels and product portfolio now firmly established. We continue to foster key partnerships and remain committed to growing sales in this key market.

New Zealand

Locally, we have released an additional dried flower product now available to patients. Sales month on month continue to increase, with highest sales reported for the month of December following from the release of this new product. In addition, we have new products currently being assessed by the NZ Ministry of Health.

United Kingdom

We successfully launched three oil products in December and these products are now available to patients via our distribution partner, Target Health. Over the coming months we will continue to be build relationships with key clinics to build awareness of Rua in this key market.

Delivering on Strategy

These achievements highlight our focus delivering our differentiated strategy with efficiency and focus. By leveraging our expertise in genetic development, and international distribution, we are creating a scalable high-value intergenerational company.

ENDS  
 

The person who authorised this announcement:

Paul Naske
Chief Executive Officer
[email protected]
+64 21 445154